15:18 , Sep 14, 2018 |  BC Week In Review  |  Company News

GNS, Amgen to use AI to explore patient response to mCRC drug Vectibix

GNS Healthcare Inc. (Cambridge, Mass), Amgen Inc. (NASDAQ:AMGN) and the Alliance for Clinical Trials in Oncology (Boston, Mass.) partnered to use artificial intelligence to identify factors that drive and predict patient responses to Amgen’s metastatic...
18:07 , Sep 7, 2018 |  BC Week In Review  |  Clinical News

FDA extends review of Tecentriq/Avastin combo for NSCLC

Roche (SIX:ROG; OTCQX:RHHBY) said FDA extended review for an sBLA for Tecentriq atezolizumab by three months to Dec. 5. The original PDUFA date was Sept. 5. The sBLA , which FDA is evaluating under Priority...
23:11 , Aug 28, 2018 |  BC Extra  |  Company News

Management tracks: BMS, Roche

Bristol-Myers Squibb Co. (NYSE:BMY) said Christopher Boerner will become EVP and Chief Commercial Officer. He succeeds Murdo Gordon, who departed the company last month to become EVP of global commercial operations at Amgen Inc. (NASDAQ:AMGN)...
20:30 , Aug 17, 2018 |  BioCentury  |  Finance

Location, location, biotech

Chinese real estate investor Xuechao Wang placed a bet on a domestic cancer start up 16 years ago, which helped pave the way for the country’s first homegrown targeted cancer therapy. Now, market growth in...
06:36 , Aug 10, 2018 |  BC Week In Review  |  Financial News

Tot raises $102M series B

Cancer company Tot Biopharm Co. Ltd. (Suzhou, China) raised $102 million on Aug. 8 in a series B round. Participants included China Universal (Cayman) GP Ltd. and other investors as well as existing investors Center...
20:32 , Aug 8, 2018 |  BC Extra  |  Financial News

Tot raises $102M series B

Cancer company Tot Biopharm Co. Ltd. (Suzhou, China) raised $102 million in a series B round. Participants included China Universal (Cayman) GP Ltd. and other investors as well as existing investors Center Laboratories Group, Vivo...
21:26 , Jul 27, 2018 |  BioCentury  |  Regulation

Biosimilar barriers

A coming showdown over anticompetitive contracting practices, coupled with an impending wave of patent expirations, could result in a wave of biosimilar approvals and launches in the U.S. over the next year, according to biosimilars...
18:11 , Jul 27, 2018 |  BC Week In Review  |  Company News

Roche, other pharmas follow suit to halt price increases

Roche (SIX:ROG; OTCQX:RHHBY) is following the trend of suspending price increases in the U.S. for this year after President Donald Trump and HHS Secretary Alex Azar publicly demanded changes in drug pricing. Roche said in a...
22:26 , Jul 20, 2018 |  BC Extra  |  Company News

Roche, other pharmas follow suit to halt price increases

Roche (SIX:ROG; OTCQX:RHHBY) is following the trend of suspending price increases in the U.S. for this year after President Donald Trump and HHS Secretary Alex Azar publicly demanded changes in drug pricing. Roche said in a...
21:52 , Jul 13, 2018 |  BioCentury  |  Strategy

Roche’s partnering priority

As James Sabry gets set to lead partnering for all of Roche pharma, his first order of business might be to build out the company’s late-stage pipeline ahead of an impending patent cliff that puts...